Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 7/20 | 0.53 |
| ▸ | CACNA1B | Q00975 | 7/20 | 0.53 |
| ▸ | CACNB1 | Q02641 | 7/20 | 0.53 |
| ▸ | CACNA1C | Q13936 | 4/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | RXRB | P28702 | 1/20 | 0.46 |
| ▸ | RXRG | P48443 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2797076 | 0.89 | CACNA2D1 (0.40) | CACNA2D1CACNA1BCACNB1CACNA1CALDH1A1 | |
| SCHEMBL2795523 | 0.87 | TSHR (0.46) | CACNA2D1CACNA1BCACNB1CACNA1CHTT | |
| SCHEMBL2796224 | 0.87 | CACNA2D1 (0.56) | CACNA2D1CACNA1BCACNB1CACNA1CHTT | |
| SCHEMBL2791261 | 0.82 | HTT (0.54) | CACNA2D1CACNA1BCACNB1CACNA1CHTT | |
| SCHEMBL2794855 | 0.82 | CACNA2D1 (0.54) | CACNA2D1CACNA1BCACNB1CACNA1CHTT | |
| SCHEMBL2794307 | 0.80 | TDP1 (0.62) | CACNA2D1CACNA1BCACNB1CACNA1CALDH1A1 | |
| SCHEMBL2791095 | 0.79 | CACNA2D1 (0.50) | CACNA2D1CACNA1BCACNB1CACNA1CHTT | |
| SCHEMBL17512449 | 0.78 | CACNA2D1 (0.81) | CACNA2D1CACNA1BCACNB1CACNA1CHTT | |
| SCHEMBL2793051 | 0.76 | ALDH1A1 (0.46) | ALDH1A1HRH3CNR1CNR2 | |
| SCHEMBL3393147 | 0.74 | CACNA2D1 (0.50) | CACNA2D1CACNA1BCACNB1CACNA1CHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168103-A1 | DIARYL PIPERIDINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2010-07-01 | — | — | US | claimed |
| EP-2061780-A1 | DIARYL PIPERIDINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | Neuromed Pharmaceuticals, Ltd. (CA) | 2009-05-27 | — | — | EP | claimed |
| WO-2008031227-A1 | DIARYL PIPERIDINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2008-03-20 | — | — | WO | claimed |
| US-20100168103-A1 | DIARYL PIPERIDINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2010-07-01 | — | — | US | disclosed |
| US-20100168103-A1 | DIARYL PIPERIDINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2010-07-01 | — | — | US | disclosed |
| US-20100168103-A1 | DIARYL PIPERIDINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2010-07-01 | — | — | US | disclosed |
| WO-2008031227-A1 | DIARYL PIPERIDINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168103-A1 | DIARYL PIPERIDINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | CACNA1C, CACNA1B, ORAI1 | CACNA2D1 22/4885CACNA1B 2/4885CACNB1 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.